Transngl Ltd Secures £55k in Early-Stage Funding for Biomedical AI Development

Transngl Ltd, a London-based company specialising in the development of AI models within the Biomedical and Neuroscience Domains, has successfully secured £55k in an early-stage funding round. This investment values the nascent firm at an estimated £1.5m post-money. The allotment date for this funding was 30 March 2026, with the filing date recorded as 5 April 2026.

Founded on 28 April 2025, Transngl Ltd addresses complex challenges in healthcare and scientific research by leveraging artificial intelligence. The company's core offering includes building sophisticated AI models for biomedical and neuroscience applications, alongside providing consultancy services in the Health AI sector. Currently, Transngl Ltd operates with a small team of four employees, reflecting its early-stage development. Specific financial metrics such as revenue, profit, or loss figures have not been publicly disclosed at this time.

The recent £55k funding round represents a foundational investment for Transngl Ltd. While the specific investors involved in this round have not been named, and details of any previous funding rounds were not available, this capital injection at a £1.5m post-money valuation underscores investor confidence in the company's specialised AI capabilities. This pre-seed funding is crucial for a young company like Transngl Ltd, enabling it to further develop its proprietary AI models and expand its consultancy offerings in a rapidly evolving field.

This funding round for Transngl Ltd occurs within a dynamic and increasingly robust UK funding landscape for deep tech and health AI. The broader deep tech sector in the UK experienced significant growth in 2025, with companies raising $4.8 billion in equity funding across 184 rounds by December, marking an 18.16% increase from the previous year. Deep tech now accounts for 31% of all UK venture capital funding, a threefold increase over the past decade. Artificial intelligence, in particular, has emerged as a dominant force within deep tech, representing 39% of all UK deep tech funding in 2025.

The health tech and biotech sectors have seen a "renaissance" in the UK, with a strong investor appetite for AI-enabled businesses. In 2025, UK venture capital deployed a record £6 billion into AI. London, where Transngl Ltd is based, stands out as a pivotal hub for healthtech and life sciences investment, with venture capital investment into London-based healthtech companies growing 11.1 times since 2016. Furthermore, in 2025, AI companies in HealthTech in London raised $643 million across four rounds by September, indicating a substantial rise in investment compared to the previous year.

Government initiatives also signal strong support for AI in healthcare. The UK Research and Innovation (UKRI) has committed a record £1.6 billion directly targeted at the AI sector for 2026 to 2030, with healthcare explicitly identified as a priority area, including funding for AI-enabled drug discovery and diagnostics. The NHS 10-Year Plan also places artificial intelligence at the centre of healthcare transformation, with a regulatory framework for AI as a medical device expected in 2026, designed to accelerate adoption.

Transngl Ltd's modest but significant early-stage funding aligns with the trend of investment in highly specialised, AI-driven solutions within the UK's burgeoning health and deep tech ecosystem. As the company continues to develop its AI models for biomedical and neuroscience applications, it operates within a supportive environment characterised by increasing investor interest and strategic governmental backing for AI innovation in healthcare.